search
Back to results

To Study the Effect of SC-FOS Prebiotics in Women With Polycystic Ovary Syndrome

Primary Purpose

Polycystic Ovary Syndrome

Status
Recruiting
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
Short Chain Fructooligosaccharides
Placebo Group
Sponsored by
Universidad Autonoma de Chihuahua
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Polycystic Ovary Syndrome focused on measuring Polycystic Ovary Syndrome, Prebiotics, Enteral Diet, Clinical Manifestations, SC-FOS

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Female sex Age 18 to 65 years Polycystic Ovary Syndrome diagnosed by specialist Useful enteral feeding Exclusion Criteria: Pregnancy Diabetes mellitus Risk of intestinal perforation

Sites / Locations

  • Hospital Central del Estado de ChihuahuaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Short Chain Fructooligosaccharides Group

Placebo Group

Arm Description

This group will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours for 10 days, diluted in 250 ml

This group will receive Corn Starch as a Placebo control 12 gr. every 24 hours for 10 days, diluted in 250 ml

Outcomes

Primary Outcome Measures

Score of Bristol Scale
Score obtained by Stool Consistency Bristol Scale: This scale consist in seven types of stool: Type 1: Separate hard lumps, like nuts (difficult to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft (average stool) Type 5: Soft blobs with clear cut edges Type 6: Fluffy pieces with ragged edges, a mushy stool (diarrhea) Type 7: Watery, no solid pieces, entirely liquid (diarrhea)
Score Short Form Health Survey (SF-36)
Short Form Health Survey (SF-36) is a measure of health-related quality-of-life: It comprises 36 questions that cover eight domains of health Limitations in physical activities because of health problems. Limitations in social activities because of physical or emotional problems Limitations in usual role activities because of physical health problems Bodily pain General mental health (psychological distress and well-being) Limitations in usual role activities because of emotional problems Vitality (energy and fatigue) General health perceptions

Secondary Outcome Measures

Full Information

First Posted
August 11, 2023
Last Updated
August 19, 2023
Sponsor
Universidad Autonoma de Chihuahua
search

1. Study Identification

Unique Protocol Identification Number
NCT05999097
Brief Title
To Study the Effect of SC-FOS Prebiotics in Women With Polycystic Ovary Syndrome
Official Title
To Study the Clinical Effect of SC-FOS Prebiotics in Enteral Diet vs. Standard Enteral Diet on Clinical Characteristics of Patients With Polycystic Ovary Syndrome According to the Rotterdam Classification in Chihuahua, Chihuahua. A Randomized Single-Blind Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
September 10, 2023 (Anticipated)
Study Completion Date
September 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad Autonoma de Chihuahua

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine if there is a difference in the clinical characteristics of patients with polycystic ovary syndrome after the administration of SC-FOS in the enteral diet compared to patients with a standard diet.
Detailed Description
The protocol will be discussed with the patients and/or relatives of the patients, who will understand the consequences and advantages of the study and will thus sign the consent. Once informed consent has been obtained, the group to which each patient belongs will be randomly assigned. Patients will be selected according to the inclusion and exclusion criteria of the population diagnosed with PCOS with useful enteral route for random assignment into two groups, one will be administered short-chain Fructooligosaccharides at a dose of 12 g every 24 hours, another group will be given saline as a placebo to the enteral diet every 24 hours for 10 days. Patients should take the solution on an empty stomach. Once the type of intervention has been determined, the patient will be given the suspensions corresponding to group 1 or placebo, with vials in which the content cannot be visualized, numbered according to the sheet obtained by the corresponding randomization. The initial evaluation will be completed with all the clinical characteristics to be evaluated. The patient will be told that every 24 hours he must take 1 suspension on an empty stomach, which will be prepared at a rate of 12 grams of SC-FOS in 15 cc of saline solution for the prebiotic preparation vs 15 cc of saline solution for the placebo group. The solution will be administered enterally for 10 consecutive days at a single dose per day, and a reassessment will be made on the seventh day of the clinical characteristics of the patients, to compare and evaluate the results.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polycystic Ovary Syndrome
Keywords
Polycystic Ovary Syndrome, Prebiotics, Enteral Diet, Clinical Manifestations, SC-FOS

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective study, randomized single blind clinical trial
Masking
Participant
Masking Description
Single (Participant)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Short Chain Fructooligosaccharides Group
Arm Type
Experimental
Arm Description
This group will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours for 10 days, diluted in 250 ml
Arm Title
Placebo Group
Arm Type
Placebo Comparator
Arm Description
This group will receive Corn Starch as a Placebo control 12 gr. every 24 hours for 10 days, diluted in 250 ml
Intervention Type
Dietary Supplement
Intervention Name(s)
Short Chain Fructooligosaccharides
Other Intervention Name(s)
Prebiotics
Intervention Description
The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo Group
Other Intervention Name(s)
Placebo
Intervention Description
This group will receive 12 g of corn starch as a control group.
Primary Outcome Measure Information:
Title
Score of Bristol Scale
Description
Score obtained by Stool Consistency Bristol Scale: This scale consist in seven types of stool: Type 1: Separate hard lumps, like nuts (difficult to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft (average stool) Type 5: Soft blobs with clear cut edges Type 6: Fluffy pieces with ragged edges, a mushy stool (diarrhea) Type 7: Watery, no solid pieces, entirely liquid (diarrhea)
Time Frame
10 days
Title
Score Short Form Health Survey (SF-36)
Description
Short Form Health Survey (SF-36) is a measure of health-related quality-of-life: It comprises 36 questions that cover eight domains of health Limitations in physical activities because of health problems. Limitations in social activities because of physical or emotional problems Limitations in usual role activities because of physical health problems Bodily pain General mental health (psychological distress and well-being) Limitations in usual role activities because of emotional problems Vitality (energy and fatigue) General health perceptions
Time Frame
10 days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female sex Age 18 to 65 years Polycystic Ovary Syndrome diagnosed by specialist Useful enteral feeding Exclusion Criteria: Pregnancy Diabetes mellitus Risk of intestinal perforation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Carolina Martinez Loya
Phone
6143543923
Ext
+52
Email
caromtzloya@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ruth Favela Ortiz
Phone
6142277559
Ext
+52
Email
rfavelaortiz@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luis B Enríquez-Sánchez
Organizational Affiliation
Universidad Autonoma de Chihuahua
Official's Role
Study Director
Facility Information:
Facility Name
Hospital Central del Estado de Chihuahua
City
Chihuahua
ZIP/Postal Code
31000
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carolina Martínez Loya, M.D.
Phone
+526143543923
Email
caromtzloya@gmail.com
First Name & Middle Initial & Last Name & Degree
Ruth S Favela Ortiz
Phone
6142277559
Ext
+52
Email
rfavelaortiz@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The data obtained from this research study will be available if requested once the study is finalized.
IPD Sharing Time Frame
The data will be available for up to five years since completion of the study.
IPD Sharing Access Criteria
The request for the data will be by e-mail

Learn more about this trial

To Study the Effect of SC-FOS Prebiotics in Women With Polycystic Ovary Syndrome

We'll reach out to this number within 24 hrs